EP1575516A4

Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis

Abstract

This record has no abstract on file.

EP1575516A4, drawing sheet 1 — Sheet 1 of 29

Term

Term ended

Projected expiry passed 26 November 2023, 2.8 years ago.

29 sheets

Sheet 1
Sheet 2
Sheet 3
Sheet 4
Sheet 5
Sheet 6
Sheet 7
Sheet 8
Sheet 9
Sheet 10
Sheet 11
Sheet 12
Sheet 13
Sheet 14
Sheet 15
Sheet 16
Sheet 17
Sheet 18
Sheet 19
Sheet 20
Sheet 21
Sheet 22
Sheet 23
Sheet 24
Sheet 25
Sheet 26
Sheet 27
Sheet 28
Sheet 29

Every citation, both waysCites: the store holds 1 of 2

Citations
Document	Relation	Office	Category	Cited during	Relevant claims
US2002172675A1	Cites	United States of America	X	Search report	1-32
KIM S ET AL: "REGULATION OF ANGIOGENESIS IN VIVO BY LIGATION OF INTEGRIN ALPHA5BETA1 WITH THE CENTRAL CELL-BINDING DOMAIN OF FIBRONECTIN", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 156, no. 4, April 2000 (2000-04-01), XP000943792, ISSN: 0002-9440	Non-patent	–	–	Search report	–
JOSIC D ET AL: "Analytical and preparative methods for purification of antibodies", FOOD TECHNOLOGY AND BIOTECHNOLOGY, ZAGREB, HR, vol. 39, no. 3, 2001, pages 215 - 226, XP002357256, ISSN: 1330-9862	Non-patent	–	–	Search report	–
VAN DER LOO JOHANNES C M ET AL: "VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin", JOURNAL OF CLINICAL INVESTIGATION, vol. 102, no. 5, 1 September 1998 (1998-09-01), pages 1051 - 1061, XP002443726, ISSN: 0021-9738	Non-patent	–	–	Search report	–
RAMAKRISHNAN VANITHA ET AL: "A function-blocking chimeric antibody, Eos200-4, against alpha5beta1 integrin inhibits angiogenesis in a monkey model.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 605 - 606, XP008081615, ISSN: 0197-016X	Non-patent	–	–	Search report	–
"Eos Biotechnology files Investigational New Drug for novel targets with anti-angiogenenic properties", 7 December 2002 (2002-12-07), XP002443727, Retrieved from the Internet <URL:http://www.pharmabiz.com/article/detnews.asp?articleid=13491&sectionid=14&z=y> [retrieved on 20070720]	Non-patent	–	–	Search report	–
"Protein Design Labs to acquire Eos Biotechnology", 7 February 2003 (2003-02-07), XP002443728, Retrieved from the Internet <URL:http://www.pharmabiz.com/article/detnews.asp?articleid=14199&sectionid=14&z=y> [retrieved on 20070720]	Non-patent	–	–	Search report	–
VARNER J A ET AL: "ANTAGONISTS OF VASCULAR CELL INTEGRIN ALPHA5BETA1 INHIBIT ANGIOGENESIS", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 98, no. 17, November 1998 (1998-11-01), pages 4166, XP000857372, ISSN: 0009-7322	Non-patent	–	–	Search report	–
HO SUN K ET AL: "The effect of a chimeric anti-integrin alpha 5 beta 1 antibody (M200) on the migration of HUVECs and human cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 45, March 2004 (2004-03-01), & 95TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ORLANDO, FL, USA; MARCH 27 -31, 2004, pages 333, XP001248675, ISSN: 0197-016X	Non-patent	–	–	Search report	–
BHASKAR VINAY ET AL: "M200 (volociximab), a chimeric antibody against integrin alpha5 betal, inhibits tumor growth by multiple mechanisms.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 1063, XP001248676, ISSN: 0197-016X	Non-patent	–	–	Search report	–
KUWADA S K: "Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody", CURRENT OPINION IN MOLECULAR THERAPEUTICS 2007 UNITED KINGDOM, vol. 9, no. 1, 2007, pages 92 - 98, XP008081479, ISSN: 1464-8431	Non-patent	–	–	Search report	–
RAMAKRISHNAN V ET AL: "Preclinical evaluation of an anti-[alpha]5[beta]1 integrin antibody as a novel anti-angiogenic agent", JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY 2006 UNITED KINGDOM, vol. 5, no. 4, 2006, pages 273 - 286, XP008081487, ISSN: 1359-4117	Non-patent	–	–	Search report	–
See also references of WO 2004056308A2	Non-patent	–	–	Search report	–

41 members in 16 offices

This recordMember, by publication datePriority claim6 more offices are in the list below

Priority claims9

Priority claims
Document	Office	Kind	Date
429743P	United States of America	–	2002-11-26
42974302	United States of America	P	2002-11-26
42974302	United States of America	P	2002-11-26
0338172	United States of America	W	2003-11-26
0338172	United States of America	W	2003-11-26
429743P	–	–	–
US20020429743P	–	–	–
US2003038172	–	–	–
WO2003US38172	–	–	–

Members41

Family members, oldest first
Document	Office	Kind
CA2507099A1	Canada	A1	2004-07-08
WO2004056308A2	World Intellectual Property Organization (WIPO)	A2	2004-07-08
AU2003298783A1	Australia	A1	2004-07-14
US2005054834A1	United States of America	A1	2005-03-10
NO20053101D0	Norway	D0	2005-06-24
MXPA05005558A	Mexico	A	2005-07-26
US2005163769A1	United States of America	A1	2005-07-28
NO20053101L	Norway	L	2005-08-26
WO2004056308A3	World Intellectual Property Organization (WIPO)	A3	2005-09-01
KR20050089151A	Republic of Korea	A	2005-09-07
EP1575516A2	European Patent Office (EPO)	A2	2005-09-21
BR0316670A	Brazil	A	2005-10-11
RU2005120019A	Russian Federation	A	2006-01-20
CN1753911A	China	A	2006-03-29
JP2006516098A	Japan	A	2006-06-22
HK1089189A1	Hong Kong, China	A1	2006-11-24
ZA200505114B	South Africa	B	2007-03-28
EP1575516A4This record	European Patent Office (EPO)	A4	2007-09-26
US7276589B2	United States of America	B2	2007-10-02
US7285268B2	United States of America	B2	2007-10-23
US2008026033A1	United States of America	A1	2008-01-31
US2008026458A1	United States of America	A1	2008-01-31
CN100369930C	China	C	2008-02-20
NZ540562A	New Zealand	A	2008-04-30
US2008260732A1	United States of America	A1	2008-10-23
RU2346701C2	Russian Federation	C2	2009-02-20
US2009259031A1	United States of America	A1	2009-10-15
US7776585B2	United States of America	B2	2010-08-17
AU2003298783B2	Australia	B2	2010-11-04
US7879987B2	United States of America	B2	2011-02-01
US7897148B2	United States of America	B2	2011-03-01
JP2011120593A	Japan	A	2011-06-23
EP2351583A1	European Patent Office (EPO)	A1	2011-08-03
JP4741242B2	Japan	B2	2011-08-03
US8017116B2	United States of America	B2	2011-09-13
US2011300133A1	United States of America	A1	2011-12-08
KR20110140143A	Republic of Korea	A	2011-12-30
EP1575516B1	European Patent Office (EPO)	B1	2012-05-30
ES2387985T3	Spain	T3	2012-10-05
US8309084B2	United States of America	B2	2012-11-13
CA2507099C	Canada	C	2013-09-24

94 legal events, as 9 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2024-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2024-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2024-01-22	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2024-01-18	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2023-12-20	Patent expired after termination of 20 yearsExpiredPE20	PE20	GB
2023-12-01	Announcement of lapse in spainLapsedFD2A	FD2A	ES
2023-11-26	Expiry of rightR071	R071	DE
2023-06-14	Opt-out of the competence of the unified patent court (upc) registeredP01	P01	EP
2023-01-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-01-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-01-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2023-01-31	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2022-12-30	Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP	PGFP	EP
2018-10-17	Fee paymentPLFP	PLFP	FR
2017-10-18	Fee paymentPLFP	PLFP	FR
2016-10-17	Fee paymentPLFP	PLFP	FR
2015-10-27	Fee paymentPLFP	PLFP	FR
2014-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-05-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2014-04-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-12-27	Change of name or company nameCD	CD	FR
2013-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-10-30	Transfer of patentPC2A	PC2A	ES
2013-10-02	Change of applicant/patenteeR081	R081	DE
2013-10-02	Change of applicant/patenteeR081	R081	DE
2013-10-02	Change of applicant/patenteeR081	R081	DE
2013-10-02	Change of applicant/patenteeR081	R081	DE
2013-10-02	Change of representativeR082	R082	DE
2013-08-28	Patent lapsedLapsedMM4A	MM4A	IE
2013-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-07-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-07-04	No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097	R097	DE
2013-06-28	Patent ceasedCeasedPL	PL	CH
2013-05-08	No opposition filedOpposition26N	26N	EP
2013-04-05	No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE	PLBE	EP
2013-04-05	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA	STAA	EP
2013-02-28	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2013-01-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-12-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-11-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-11-30	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-11-15	Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05	MK05	AT
2012-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-10-31	Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25	PG25	EP
2012-10-05	Definitive protectionFG2A	FG2A	ES
2012-09-19	Discontinued in the netherlands as no translation has been filedVDEP	VDEP	NL
2012-07-19	Dpma publication of mentioned ep patent grantGrantedR096	R096	DE
2012-06-20	European patents granted designating irelandGrantedFG4D	FG4D	IE
2012-06-15	Reference to at number (ep patent validated in austria)REF	REF	AT
2012-05-31	European patent takes effect as a national patent in ch/liEP	EP	CH
2012-05-30	Designated contracting statesAK	AK	EP
2012-05-30	European patent grantedGrantedFG4D	FG4D	GB
2012-04-27	(expected) grantORIGINAL CODE: 0009210GRAA	GRAA	EP
2012-04-16	Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS	GRAS	EP
2012-02-22	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2012-02-22	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2012-02-22	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2012-02-22	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2012-02-22	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2012-02-09	Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP	GRAP	EP
2012-01-19	Amendment of ipc main classPREVIOUS MAIN CLASS: C07K0016000000R079	R079	DE
2012-01-19	Amendment of ipc main classPREVIOUS MAIN CLASS: A61K0006000000R079	R079	DE
2011-08-24	Party data changed (applicant data changed or rights of an application transferred)RAP1	RAP1	EP
2011-01-12	Party data changed (applicant data changed or rights of an application transferred)RAP1	RAP1	EP
2008-03-19	First examination report despatched17Q	17Q	EP
2007-12-26	Party data changed (applicant data changed or rights of an application transferred)RAP1	RAP1	EP
2007-09-26	Supplementary search report drawn up and despatchedA4	A4	EP
2007-09-19	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-09-19	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-09-19	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-09-19	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-09-19	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2007-09-19	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2006-08-23	Party data changed (applicant data changed or rights of an application transferred)RAP1	RAP1	EP
2006-03-29	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2006-03-29	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2006-03-29	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2006-03-15	Request for extension of the european patent (deleted)DAX	DAX	EP
2005-10-26	Designated contracting statesAK	AK	EP
2005-10-26	Request for extension of the european patentAX	AX	EP
2005-09-21	Request for examination filed17P	17P	EP
2005-09-21	Designated contracting statesAK	AK	EP
2005-09-21	Request for extension of the european patentAX	AX	EP
2005-09-09	Availability of information related to the publication of the international search reportORIGINAL CODE: 0009015PUAK	PUAK	EP
2005-08-05	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI	EP

Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis

Abstract

Term

Priority claims9

Members41

Over the term

Events

Numbers

Titles3

Classification

Designated states1